Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Announces Closing of its $60.0 Million Public Offering of Common Shares
January 27, 2020
Xenon Announces Pricing of $60.0 Million Public Offering of Common Shares
January 22, 2020
Xenon Announces Proposed Public Offering of Common Shares
January 22, 2020
Xenon Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
January 13, 2020
Xenon Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
December 7, 2019
Xenon Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
December 6, 2019
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
December 2, 2019
Product Pipeline
* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
